Last reviewed · How we verify
Oxytocin + misoprostol
Oxytocin stimulates uterine contractions while misoprostol enhances uterine sensitivity and contractility to promote labor induction or augmentation and reduce postpartum hemorrhage.
Oxytocin stimulates uterine contractions while misoprostol enhances uterine sensitivity and contractility to promote labor induction or augmentation and reduce postpartum hemorrhage. Used for Labor induction, Labor augmentation, Prevention and treatment of postpartum hemorrhage.
At a glance
| Generic name | Oxytocin + misoprostol |
|---|---|
| Sponsor | Ain Shams Maternity Hospital |
| Drug class | Uterotonic agents |
| Target | Oxytocin receptor; prostaglandin E1 receptor (EP receptor) |
| Modality | Small molecule |
| Therapeutic area | Obstetrics |
| Phase | FDA-approved |
Mechanism of action
Oxytocin is a posterior pituitary hormone that binds to oxytocin receptors on uterine smooth muscle, triggering rhythmic contractions. Misoprostol, a prostaglandin E1 analog, sensitizes the uterus to oxytocin and independently promotes uterine contractions. Together, they provide synergistic effects for labor induction, augmentation, and management of postpartum hemorrhage.
Approved indications
- Labor induction
- Labor augmentation
- Prevention and treatment of postpartum hemorrhage
Common side effects
- Uterine hyperstimulation
- Nausea
- Vomiting
- Diarrhea
- Abdominal pain
- Fever
- Flushing
Key clinical trials
- Combined Use of Oxytocin and Misoprostol in the Prevention of Post Partum Haemorrhage (PHASE4)
- Cooling the Uterus in C-section After Dysfunctional Labor (NA)
- Carbetocin vs Misoprostol for Postpartum Hemorrhage Prevention (NA)
- Oxytocin vs Prostaglandins for Labor Induction of Women With an Unfavorable Cervix After 24h of Cervical Ripening (PHASE3)
- Rectal Misoprostol for Reducing Blood Loss in Elective Cesarean Section (NA)
- PROMMO Trial: Oral Misoprostol vs IV Oxytocin (EARLY_PHASE1)
- Tranexamic Acid Versus Sublingual Misoprostol in Reducing Blood Loss During Elective CS in High Risk Cases (PHASE2)
- Comparison of the Efficacy of Misoprostol and Tranexamic Acid for Postpartum Hemorrhage Prophylaxis in Cesarean Delivery
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oxytocin + misoprostol CI brief — competitive landscape report
- Oxytocin + misoprostol updates RSS · CI watch RSS
- Ain Shams Maternity Hospital portfolio CI